"Etanercept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.
Descriptor ID |
D000068800
|
MeSH Number(s) |
D12.776.124.486.485.114.619.393.261 D12.776.124.790.651.114.619.393.261 D12.776.377.715.548.114.619.393.261 D12.776.543.750.705.852.760.232
|
Concept/Terms |
TNFR-Fc Fusion Protein- TNFR-Fc Fusion Protein
- Fusion Protein, TNFR-Fc
- Protein, TNFR-Fc Fusion
- TNFR Fc Fusion Protein
- TNR-001
- TNR001
- TNR 001
- 001, TNR
- TNT Receptor Fusion Protein
- TNTR-Fc
|
Below are MeSH descriptors whose meaning is more general than "Etanercept".
Below are MeSH descriptors whose meaning is more specific than "Etanercept".
This graph shows the total number of publications written about "Etanercept" by people in this website by year, and whether "Etanercept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 2 | 2 |
2009 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2012 | 0 | 1 | 1 |
2016 | 1 | 1 | 2 |
2017 | 21 | 18 | 39 |
2018 | 6 | 19 | 25 |
2019 | 2 | 10 | 12 |
2020 | 0 | 3 | 3 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Etanercept" by people in Profiles.
-
SARS-CoV-2 Serologic Immune Response in Exogenously Immunosuppressed Patients. J Appl Lab Med. 2021 03 01; 6(2):486-490.
-
Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches. J Alzheimers Dis. 2021; 79(3):931-948.
-
Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center. Dermatol Ther. 2021 Jan; 34(1):e14623.
-
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II. Dermatology. 2021; 237(1):13-14.
-
Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al. Ann Rheum Dis. 2021 05; 80(5):e80.
-
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'. Ann Rheum Dis. 2021 05; 80(5):e79.
-
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF a for Inflammatory Rheumatic Disease]. Pan Afr Med J. 2020; 35(Suppl 2):134.
-
Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int. 2020 09; 40(9):1423-1431.
-
Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report. J Korean Med Sci. 2020 Jun 01; 35(21):e201.
-
Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis. 2020 09; 79(9):1251-1252.